<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02231931</url>
  </required_header>
  <id_info>
    <org_study_id>352.2082</org_study_id>
    <secondary_id>2014-001940-40</secondary_id>
    <nct_id>NCT02231931</nct_id>
  </id_info>
  <brief_title>Drug-drug Interaction Between Digoxin, Furosemide, Metformin, and Rosuvastatin</brief_title>
  <official_title>Relative Bioavailability of a Single Oral Dose of Digoxin, Furosemide, Metformin, and Rosuvastatin Given Alone and All Together as a Cocktail, and Investigation of the Effect of Increased Doses of Metformin or Furosemide on Relative Bioavailability of the Other Cocktail Compounds in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To investigate the mutual interaction potential of digoxin, furosemide, metformin, and
      rosuvastatin when given alone or together as a cocktail, and to investigate the effect of
      high doses of metformin or furosemide on pharmacokinetics of the other cocktail compounds
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Digoxin, Metformin, Rosuvastatin: AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point)</measure>
    <time_frame>up to 96 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Furosemide: AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point)</measure>
    <time_frame>up to 36 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Furosemide: Cmax (maximum measured concentration of the analyte in plasma)</measure>
    <time_frame>up to 36 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Digoxin, Metformin, Rosuvastatin: Cmax (maximum measured concentration of the analyte in plasma)</measure>
    <time_frame>up to 96 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Furosemide: AUC0-inf (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)</measure>
    <time_frame>up to 36 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Digoxin, Metformin, Rosuvastatin: AUC0-inf (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)</measure>
    <time_frame>up to 96 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>A (Reference 1) Digoxin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 tablet as single dose, fasted</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B (Reference 2) Furosemide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral solution, as single dose, fasted</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C (Reference 3) Metformin hydrochloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 film-coated tablet as single dose, fasted</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D (Reference 4) Rosuvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 film-coated tablet as single dose, fasted</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E (Test) 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Digoxin (1 tablet), Furosemide (0.5 mL oral solution), Metformin hydrochloride (1 film-coated tablet), Rosuvastatin (1 film-coated tablet), fasted</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F (Test 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Digoxin (1 tablet), Furosemide (0.5 mL oral solution), Metformin hydrochloride (2 film-coated tablets), Rosuvastatin (1 film-coated tablet), fasted</description>
  </arm_group>
  <arm_group>
    <arm_group_label>G (Test 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Digoxin (1 tablet), Furosemide (2.0 mL oral solution), Metformin hydrochloride (1 film-coated tablet), Rosuvastatin (1 film-coated tablet), fasted</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Digoxin</intervention_name>
    <description>single dose, fasted</description>
    <arm_group_label>A (Reference 1) Digoxin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>single dose, fasted</description>
    <arm_group_label>D (Reference 4) Rosuvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Digoxin, Furosemide, Metformin hydrochloride, Rosuvastatin</intervention_name>
    <description>fasted</description>
    <arm_group_label>E (Test) 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Digoxin, Furosemide, Metformin hydrochloride, Rosuvastatin</intervention_name>
    <description>fasted</description>
    <arm_group_label>G (Test 3)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin hydrochloride</intervention_name>
    <description>single dose, fasted</description>
    <arm_group_label>C (Reference 3) Metformin hydrochloride</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Digoxin, Furosemide, Metformin hydrochloride, Rosuvastatin</intervention_name>
    <description>fasted</description>
    <arm_group_label>F (Test 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Furosemide</intervention_name>
    <description>single dose, fasted</description>
    <arm_group_label>B (Reference 2) Furosemide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Healthy male subjects according to the investigatorÂ´s assessment, based on a complete
             medical history including a physical examination, vital signs (Blood Pressure, Pulse
             Rate), 12-lead Electrocardiogram, and clinical laboratory tests

          2. Age of 18 to 50 years (incl.)

          3. Body Mass Index of 18.5 to 29.9 kg/m2 (incl.)

          4. Signed and dated written informed consent prior to admission to the study in
             accordance with Good Clinical Practice (GCP) and local legislation

        Exclusion criteria:

          1. Any finding in the medical examination (including Blood Pressure, Pulse Rate, or
             Electrocardiogram) is deviating from normal and judged as clinically relevant by the
             investigator

          2. Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg,
             diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the
             range of 50 to 90 bpm

          3. Any laboratory value outside the reference range that the investigator considers to be
             of clinical relevance

          4. Any evidence of a concomitant disease judged as clinically relevant by the
             investigator

          5. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological, or hormonal disorders

          6. Surgery of the gastrointestinal tract that could interfere with kinetics of the trial
             medication (except appendectomy and simple hernia repair)

          7. Diseases of the central nervous system (including but not limited to any kind of
             seizures or stroke), and other relevant neurological or psychiatric disorders
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>352.2082.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Biberach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2014</study_first_submitted>
  <study_first_submitted_qc>September 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2014</study_first_posted>
  <last_update_submitted>January 22, 2015</last_update_submitted>
  <last_update_submitted_qc>January 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Digoxin</mesh_term>
    <mesh_term>Furosemide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

